Email this article 
Possibility to use Ademetionine for the treatment of psoriaticpatients with a pathology of the hepatobiliary system
- Authors: Matusevich SL1, Medvedeva IV1, Matusevich SL1, Medvedeva IV1
-
Affiliations:
- Issue: Vol 86, No 6 (2010)
- Pages: 77-82
- Section: Articles
- Submitted: 11.03.2020
- Published: 15.12.2010
- URL: https://vestnikdv.ru/jour/article/view/819
- DOI: https://doi.org/10.25208/vdv819
- ID: 819
Cite item
Full Text
Abstract
The endogenous intoxication syndrome manifested in the form of excessive accumulation of low and mean molar mass substances
in plasma and urine as well as increased blood plasma concentrations of malonic dialdehyde against the background
of reduced alpha-tocopherol was revealed in psoriatic patients with the concomitant hepatobiliary system pathology. Application
of Ademetionine in the dose of 800 mg per day for 15 days as a part of the complex therapy for such patients as opposed to the
patients receiving standard therapy resulted in reliable reduction in the severity of clinical manifestations of the disease and PASI
value as well as decrease in the concentration of low and mean molecular mass substances in plasma and erythrocytes, reduction
in the blood plasma malonic dialdehyde concentration and increase in alpha-tocopherol.
in plasma and urine as well as increased blood plasma concentrations of malonic dialdehyde against the background
of reduced alpha-tocopherol was revealed in psoriatic patients with the concomitant hepatobiliary system pathology. Application
of Ademetionine in the dose of 800 mg per day for 15 days as a part of the complex therapy for such patients as opposed to the
patients receiving standard therapy resulted in reliable reduction in the severity of clinical manifestations of the disease and PASI
value as well as decrease in the concentration of low and mean molecular mass substances in plasma and erythrocytes, reduction
in the blood plasma malonic dialdehyde concentration and increase in alpha-tocopherol.
About the authors
S L Matusevich
Email: petrov@tokb.ru
I V Medvedeva
Email: petrov@tokb.ru
S L Matusevich
I V Medvedeva
References
- Langley R.G.B. Krueger G. G., Griffiths C. E. M. Psoriasis: epidemiology, clinical fea-tures, and quality of life. Annals of the Rheumatic Diseases 2005;64: 18-23.
- Скрипкин Ю.К. Кожные и венерические болезни в 2 томах. Издательство Медицина, 2006.
- Химкина Л.Н., Добротина Н.А., Копытова Т.В. Значение эндогенной интоксикации при хронических дерматозах. Методы коррекции. Вестн. дерматол. 2001; 5: 40-43.
- Копытова Т.В., Химкина Л.Н., Суздальцева И.В. Окислительный стресс и эндотоксемия у больных тяжелыми распространенными дерматозами. Соврем. пробл. дерматовенерол. иммунол. и врач. косметол. 2009; 2: 10-13.
- Бурневич Э.З., Щаницына С.Е. Современные подходы к лечению неалкогольной жировой болезни печени. Гепатологический форум. М., 2006:15-20.
- Подымова С.Д., Надинская М.Ю. Оценка эффективности препарата гептрал у больных хроническими диффузными заболеваниями печени с синдромом внутрипеченочного холестаза . Клин. мед., 1998; 10: 45-48.
- Fiorelli G. S-adenosylmethionine in the treatment of intragepatic cholestasis of chronic liver disease: a field trial. Current Therapeutic Research 1999; 60:123-126.
- Galan A. I., Minoz M. E., Palomero J. et al. Role of S-adenosylmethionine on the hepa-tobiliary homeostasis of glutathione during cyclosporine A treatment. J. Physiol Bio-chem 2000;56:189-200.
- McClain CJ, Hill DB, Song Z. S-adenosylmethionine, cytokines, and alcoholic liver dis-ease. Alcohol 2002; 27:185-192.
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).